Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2017, Article ID 5078565, 5 pages
https://doi.org/10.1155/2017/5078565
Clinical Study

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

1Department of Ophthalmology, Peking University People’s Hospital, Beijing Key Laboratory for the Diagnosis and Treatment of Retinal and Choroid Diseases, Beijing, China
2Department of Ophthalmology, China-Japan Friendship Hospital, Beijing, China

Correspondence should be addressed to Yi Chen; moc.361@iynehcrd and Xiaoxin Li; moc.361@nixoaixilrd

Received 31 July 2016; Revised 26 January 2017; Accepted 27 February 2017; Published 9 April 2017

Academic Editor: Terri L. Young

Copyright © 2017 Qinrui Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Martinez-Castellanos, S. Schwartz, M. L. Hernandez-Rojas et al., “Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up,” Retina, vol. 33, no. 2, pp. 329–338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Romagnoli, “Risk factors and growth factors in ROP,” Early Human Development, vol. 85, no. 10 Supplement, pp. S79–S82, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. F. M. Mutlu and S. U. Sarici, “Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options,” International Journal of Ophthalmology, vol. 6, no. 2, pp. 228–236, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. N. Chen, I. Lian, Y. C. Hwang et al., “Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab,” Retina, vol. 35, no. 4, pp. 667–674, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. M. J. Kim, S. J. Kim, and Y. S. Yu, “The risk for retinal detachment associated with hemorrhages pre- and postlaser treatment in retinopathy of prematurity,” Retina, vol. 28, no. 10, pp. 1451–1457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Hapsari and R. S. Sitorus, “Intravitreal bevacizumab in retinopathy of prematurity: inject or not?” Asia-Pacific Journal of Ophthalmology, vol. 3, no. 6, pp. 368–378, 2014. View at Publisher · View at Google Scholar
  7. H. A. Mintz-Hittner, K. A. Kennedy, and A. Z. Chuang, “Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity,” The New England Journal of Medicine, vol. 364, no. 7, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. D. M. Moshfeghi and A. M. Berrocal, “Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice,” Ophthalmology, vol. 118, no. 7, pp. 1227–1228, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Giannantonio, P. Papacci, F. Cota et al., “Analysis of risk factors for progression to treatment-requiring ROP in a single neonatal intensive care unit: is the exposure time relevant?” The Journal of Maternal-Fetal & Neonatal Medicine: The Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, vol. 25, no. 5, pp. 471–477, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Sanghi, M. R. Dogra, D. Katoch, and A. Gupta, “Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation,” American Journal of Ophthalmology, vol. 155, no. 1, pp. 159–164.e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. N. Menke, C. Framme, M. Nelle, M. R. Berger, V. Sturm, and S. Wolf, “Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease,” BMC Ophthalmology, vol. 15, p. 20, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Feng, J. Qian, Y. Jiang et al., “Efficacy of primary intravitreal ranibizumab for retinopathy of prematurity in China,” Ophthalmology, vol. 124, no. 3, pp. 408–409, 2017. View at Google Scholar
  13. R. K. Wong, S. Hubschman, and I. Tsui, “Reactivation of retinopathy of prematurity after ranibizumab treatment,” Retina, vol. 35, no. 4, pp. 675–680, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. M. K. Erol, D. T. Coban, E. S. Sari et al., “Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity,” Arquivos Brasileiros de Oftalmologia, vol. 78, no. 6, pp. 340–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Hoerster, P. Muether, C. Dahlke et al., “Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity,” Acta Ophthalmologica, vol. 91, no. 1, pp. e74–e75, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Watts, G. G. Adams, R. M. Thomas, and C. Bunce, “Intraventricular haemorrhage and stage 3 retinopathy of prematurity,” The British Journal of Ophthalmology, vol. 84, no. 6, pp. 596–599, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. Pollack and L. Tychsen, “Prevalence of retinal hemorrhages in infants after extracorporeal membrane oxygenation,” American Journal of Ophthalmology, vol. 121, no. 3, pp. 297–303, 1996. View at Publisher · View at Google Scholar
  18. M. Ehrenberg, R. J. Thresher, and R. Machemer, “Vitreous hemorrhage nontoxic to retina as a stimulator of glial and fibrous proliferation,” American Journal of Ophthalmology, vol. 97, no. 5, pp. 611–626, 1984. View at Publisher · View at Google Scholar
  19. B. C. Toy, I. H. Schachar, G. S. Tan, and D. M. Moshfeghi, “Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity,” Ophthalmology, vol. 123, no. 10, pp. 2166–2175, 2016. View at Publisher · View at Google Scholar